Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tango Therapeutics Inc.

4.26
+0.750021.37%
Post-market: 4.360.0999+2.35%19:58 EDT
Volume:9.19M
Turnover:38.92M
Market Cap:461.76M
PE:-3.54
High:4.71
Open:3.60
Low:3.58
Close:3.51
Loading ...

Tango Therapeutics Inc. Conducted Annual Stockholders' Meeting

Reuters
·
Yesterday

Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer

MT Newswires Live
·
21 May

Tango Therapeutics Announces First Patient Dosed in Tng456 Phase 1/2 Trial in Patients With Mtap-Deleted Glioblastomas and Other Solid Tumors

THOMSON REUTERS
·
21 May

BRIEF-Tango Therapeutics Files For Mixed Shelf Of Up To $400 Million

Reuters
·
13 May

Tango Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
12 May

Tango Therapeutics Q1 EPS $(0.36) Misses $(0.35) Estimate, Sales $5.39M Miss $6.69M Estimate

Benzinga
·
12 May

Press Release: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Dow Jones
·
12 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 May

Tango Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
10 May

Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
05 May

Tango Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
02 May

Press Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Dow Jones
·
01 May

Analysts Are Bullish on These Healthcare Stocks: GeoVax Labs (GOVX), Tango Therapeutics (TNGX)

TIPRANKS
·
16 Apr

Tango Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Apr

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

GlobeNewswire
·
26 Mar

Tango Therapeutics (TNGX) Receives a Buy from Barclays

TIPRANKS
·
02 Mar

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint

Simply Wall St.
·
28 Feb

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
27 Feb

BRIEF-Tango Therapeutics Q4 Basic EPS USD -0.35

Reuters
·
27 Feb

Tango Therapeutics Q4 Basic EPS USD -0.35

THOMSON REUTERS
·
27 Feb